Pharmaceutical · Fiscal year end Sep 30

Fuji Pharma Co.,Ltd.

4554

富士製薬工業株式会社

FIGI BBG000F7NGK44554.T4554 JPCorp. no. 5010001084045

Latest half-year results

First half · fiscal year to 2026-09 · filed 2026-05-13

For the first half of the fiscal year to 2026-09: Revenue ¥29.7 billion (+23.3% YoY), Ordinary income ¥4.3 billion (+93.0% YoY), Net income ¥0.7 billion (-44.6% YoY).

	This period	Year on year
Revenue	¥29.7bn	+23.3%
Ordinary profit	¥4.3bn	+93.0%
Net profit to owners	¥713m	-44.6%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4554/earnings-releases.

Financials

Japan GAAP · consolidated · fiscal year to 2025-09-30

Revenue: ¥51.7bn
Net income: ¥3.0bn
ROE: 6.5%
Equity ratio: 50.2%
Dividend / share: ¥45.5
Employees: 1,760

Revenue · ¥bn

Net income · ¥bn

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2025-09-30	¥51.7bn	¥3.0bn	¥93.4bn	¥46.9bn	6.5%	¥122.94	¥5.8bn
2024-09-30	¥46.1bn	¥6.1bn	¥90.0bn	¥45.6bn	14.2%	¥252.85	¥4.2bn
2023-09-30	¥40.9bn	¥3.4bn	¥85.3bn	¥41.2bn	8.9%	¥141.37	¥1.9bn
2022-09-30	¥35.4bn	¥2.7bn	¥75.5bn	¥35.8bn	7.9%	¥111.01	−¥0.7bn
2021-09-30	¥34.0bn	¥2.4bn	¥64.2bn	¥32.7bn	6.7%	¥90.54	¥6.0bn

Indicators

Computed by us from filings · fiscal year to 2025-09-30

Metric	Value	Percentile among listed companies
ROE, %	6.5	35.5
Ordinary margin	0.0863	60.4
Equity ratio, %	50.2	41.6
Revenue growth	0.1201	74.5
Net income growth	-0.5119	13.2
Operating cash flow / assets	0.0621	48.6

Policy-uncertainty measure0.00 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change 0.00pt in 90 days; 0.2% held by other listed companies.

Results wording balance: 0.00. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥26.2bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥131m, 2.3% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4554/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2025-12-18: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断いたしました。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Latest voting result: 2025-12-19 · 剰余金処分の件 · passed. /v1/companies/4554/voting

Ownership changes

All companies →

2026-07-31

Decrease−1.68pt

individual filer reduced holdings in Fuji Pharma Co.,Ltd. (4554) to 29.99% from 31.67%.

S100YOUWOriginal filing (PDF, Japanese)
2026-06-24

Amendment−1.07pt

individual filer filed a correction to a 5% report on Fuji Pharma Co.,Ltd. (4554).

S100YINTOriginal filing (PDF, Japanese)
2026-06-23

Decrease−1.07pt

individual filer reduced holdings in Fuji Pharma Co.,Ltd. (4554) to 31.67% from 32.74%.

S100Y809Original filing (PDF, Japanese)
2026-05-29

Decrease−1.03pt

individual filer reduced holdings in Fuji Pharma Co.,Ltd. (4554) to 32.74% from 33.77%.

S100Y1THOriginal filing (PDF, Japanese)
2026-05-29

Threshold

Holdings of individual filer in Fuji Pharma Co.,Ltd. (4554) moved below 33.4% (33.77% -> 32.74%).

S100Y1THOriginal filing (PDF, Japanese)
2026-03-19

Below 5%−1.55pt

Nomura Securities Co.,Ltd. cut holdings in Fuji Pharma Co.,Ltd. (4554) to 4.75% from 6.30%, below the 5% threshold.

S100XRM5Filer profile Original filing (PDF, Japanese)
2026-03-05

Decrease−2.63pt

Nomura Securities Co.,Ltd. reduced holdings in Fuji Pharma Co.,Ltd. (4554) to 6.30% from 8.93%.

S100XOM2Filer profile Original filing (PDF, Japanese)
2026-02-20

Decrease−0.83pt

Nomura Securities Co.,Ltd. reduced holdings in Fuji Pharma Co.,Ltd. (4554) to 8.93% from 9.76%.

S100XMJAFiler profile Original filing (PDF, Japanese)
2026-02-12

Decrease−1.03pt

Nomura Securities Co.,Ltd. reduced holdings in Fuji Pharma Co.,Ltd. (4554) to 9.76% from 10.79%.

S100XKINFiler profile Original filing (PDF, Japanese)
2026-02-12

Threshold

Holdings of Nomura Securities Co.,Ltd. in Fuji Pharma Co.,Ltd. (4554) moved below 10% (10.79% -> 9.76%).

S100XKINFiler profile Original filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
individual filer	2023-02-10 – 2026-07-31	-1,400,000	−5.55pt	¥1,035	¥1,035–1,035
野村アセットマネジメント株式会社	2024-06-10 – 2026-02-06	-25,000	−0.11pt	¥1,511.27	¥1,224–1,972
野村證券株式会社	2024-06-07 – 2026-02-06	+2,314,426	+7.07pt	¥1,863.35	¥1,093–2,177
NOMURA INTERNATIONAL PLC	2024-06-07 – 2025-08-01	+37,875	+0.21pt	¥1,425.57	¥1,184–1,565
individual filer	2023-02-10 – 2023-02-10	+1,000,000	+4.04pt	¥1,035	¥1,035–1,035

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4554/trades.

5% filings

Large shareholding reports on 4554

Filed	Filer	Stake	Change	Stated purpose
2026-07-31	individual filer	29.99%	−1.68pt	—
2026-06-24	individual filer	31.67%	−1.07pt	—
2026-06-23	individual filer	31.67%	−1.07pt	—
2026-05-29	individual filer	32.74%	−1.03pt	—
2026-03-19	Nomura Securities Co.,Ltd.	4.75%	−1.55pt	—
2026-03-05	Nomura Securities Co.,Ltd.	6.30%	−2.63pt	—
2026-02-20	Nomura Securities Co.,Ltd.	8.93%	−0.83pt	—
2026-02-12	Nomura Securities Co.,Ltd.	9.76%	−1.03pt	—
2025-08-08	Nomura Securities Co.,Ltd.	10.79%	−7.66pt	—
2024-08-13	Nomura Securities Co.,Ltd.	18.45%	—	—

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: 1 issues
Book value: ¥5.1bn
Sold in the year: — — issues
Bought in the year: — — issues
Mutual, both reports: 0
Held by listed cos.: 2

Holds	Book value	Shares vs. prior year	Mutual
Alvotech Holding S.A.	¥5,084m	0.0%	no

Held by: Astena Holdings Co., Ltd. 8095, ASAHI PRINTING CO.,LTD. 3951

Purposes, all holdings and mutual flags via /v1/companies/4554/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2025-09-30

Shareholder	Shares	Ratio
有限会社FJP	4,307,000	17.58%
individual holder	3,052,000	12.46%
日本マスタートラスト信託銀行株式会社(信託口)	2,159,000	8.81%
individual holder	1,240,000	5.06%
Lotus Japan Holdings合同会社	1,219,000	4.98%
株式会社日本カストディ銀行(信託口)	1,046,000	4.27%
株式会社Yamhill Sciences	1,000,000	4.08%
individual holder	446,000	1.82%
公益財団法人今井精一記念財団	400,000	1.63%
富士製薬工業従業員持株会	372,000	1.52%

U.S. funds holding 4554

SEC Form N-PORT, reports to 2026-07-31

35 U.S. funds held 1,248,590 shares worth $15.4m.

Fund	Shares	Value	% of fund	As of
Avantis International Small Cap Value ETF American Century ETF Trust	183,000	$2.7m	0.014%	2026-05-31
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS	198,497	$2.3m	0.000%	2026-07-31
DFA INTERNATIONAL SMALL CAP VALUE PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC	151,200	$1.8m	0.012%	2026-07-31
VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS	129,413	$1.6m	0.001%	2026-06-30
Dimensional International Small Cap Value ETF Dimensional ETF Trust	121,999	$1.4m	0.029%	2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4554
GET /v1/companies/4554/financials
GET /v1/companies/4554/details
GET /v1/companies/4554/segments
GET /v1/companies/4554/voting
GET /v1/companies/4554/tender-offers
GET /v1/companies/4554/indicators
GET /v1/companies/4554/earnings-releases
GET /v1/events?ticker=4554
GET /v1/companies/4554/trades         
GET /v1/companies/4554/cross-holdings 
GET /v1/companies/4554/brief

Plans from $9 a month · Documentation